Tamoxifen Sensitivity-Testing of Glioblastomas: Comparison of in Vitro and in Vivo Results

Puchner, M. J. A.; Giese, Alf; Zapf, S.; Grebe, Martin; Westphal, Manfred

doi:10.1007/s007010170061

Cited by 10 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tamoxifen is widely used to treat breast cancer and is also employed as an adjuvant treatment with modest efficacy in glial neoplasms (Chamberlain and Kormanik 1999;Puchner et al 2001). The general mechanisms of anti-estrogen action have been studied extensively.…”

Section: Discussionmentioning

confidence: 99%

Estrogen receptor beta (ER?) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm

Batistatou¹,

Stefanou²,

Goussia³

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Estrogen receptor beta (ER?) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm

Batistatou¹,

Stefanou²,

Goussia³

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…However, considering the available knowledge about the treatment of glioblastomas with tamoxifen, a response rate of approximately 30% may be expected. 2 Although the degree of estrogen antagonism provoked by tamoxifen vfries with species, tissue and parameters studied, 3 it seems that some glioma cells are tamoxifen resistant or acquire resistance.…”

mentioning

confidence: 98%

Comparison of the Antiproliferative Properties of Antiestrogenic Drugs (Nafoxidine and Clomiphene) on Glioma Cells In Vitro

Yaz

Kabadere²,

Öztopçu³

et al. 2004

American Journal of Clinical Oncology

View full text Add to dashboard Cite

The antitumoral activity of nonsteroidal antiestrogens on C6 and low passage of human glioma cells was investigated. Tamoxifen and its metabolite, 4-hydroxytamoxifen, did not influence viability of the human cells, but tamoxifen had a limited antiproliferative effect on C6 cells (IC50: 49 micromol/l). The derivatives of tamoxifen, nafoxidine and clomiphene, caused reduction of living cell number in a dose-dependent manner. These two drugs showed differences in their potency following 24-hour incubation in a humidified atmosphere with 37 degrees C and 5% CO2. Obtained from a tetrazolium-formazan growth rate assay, IC50 of nafoxidine for C6 cells was calculated as 44 micromol/l and for the human cells as 16.5 micromol/l. The calculated IC50 dose of clomiphene for C6 is 16 micromol/l and for the human cells 13 micromol/l. Compared to the other drugs we used, it is clear that clomiphene is the most efficient inhibitor of C6 and the human glioma cells. These preliminary results suggest that nafoxidine and clomiphene possess antiproliferative effect on two different sources of glioma cells and therefore, instead of tamoxifen, multiple activities of these drugs may enable their use in combination therapy of glioblastoma malignancies.

show abstract

Chemotherapy of cerebral gliomas directed by the chemosensitivity test in vitro: a clinical study

Yu¹,

Zhou

Wang

et al. 2007

Chinese German J Clin Oncol

View full text Add to dashboard Cite

Tamoxifen Sensitivity-Testing of Glioblastomas: Comparison of in Vitro and in Vivo Results

Abstract: Combining the results obtained from our human and mouse studies, it has to be postulated that host factors other than the sensitivity to TAM of the individual cell, determine the efficacy of TAM-treatment in vivo.

Cited by 10 publications

References 31 publications

Estrogen receptor beta (ER?) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm

Estrogen receptor beta (ER?) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm

Comparison of the Antiproliferative Properties of Antiestrogenic Drugs (Nafoxidine and Clomiphene) on Glioma Cells In Vitro

Chemotherapy of cerebral gliomas directed by the chemosensitivity test in vitro: a clinical study

Contact Info

Product

Resources

About